Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Paper Alert: Malformed Mitochondria in the Latest TDP-43 Mouse
16 August 2010. There is a new TDP-43 mouse in town. Having made its debut in Honolulu last month (see ARF related news story), the wild-type TDP-43-expressing animal from the Mayo Clinic in Jacksonville, Florida, is now in print in the August 11 Journal of Neuroscience.

Researchers, led by first author Ya-Fei Xu and senior authors Jada Lewis and Leonard Petrucelli, engineered mice that carry the wild-type human TDP-43 gene with the PrP promoter, so the protein is expressed in the brain and spinal cord. Homozygotes made approximately 2.5 times the TDP-43 normally found in mice. The human version actually edged out the mouse gene expression; transgenic animals had less mouse TDP-43 than non-transgenic mice, although they had more total TDP-43 protein.

Like previously reported mice that carry mutant human TDP-43 (TDP-43-A315T) driven by the PrP promoter (see ARF related news story on Wegorzewska et al., 2009), the Mayo Clinic animals exhibited low body and brain weights, as well as an impaired, “swimming” gait. These two PrP-based models, as well as mice with wild-type human TDP-43 with the mouse Thy-1 neuronal promoter (Wils et al., 2010), share insoluble TDP-43 aggregates and carboxyl-terminal truncation of the protein, both of which have been linked to disease pathology. As with the other models, the Mayo team found that TDP-43 was mostly nuclear, with occasional cytoplasmic redistribution that is not as severe as in human amyotrophic lateral sclerosis.

In addition, the Mayo scientists noticed large eosinophilic aggregates in the cytoplasm of spinal motor neurons in their model animals. When they examined these formations with electron microscopy, they discovered the aggregates were made of abnormal mitochondria. These mitochondrial clusters had fewer inner membrane folds, or cristae, than normal and vacuoles within the matrix, suggesting they were degenerating.

Mitochondria are always splitting up, via fission, and joining together, via fusion. If these processes were altered, it might cause abnormal aggregations. Accordingly, the scientists examined the fission-fusion machinery in the TDP-43 mice. The fission system, represented by Fis1 and phosphorylated DLP1, was upregulated in the model animals. Conversely, fusion protein mitofusin 1 levels dropped in animals with high levels of human TDP-43. Abnormal mitochondrial formations have been linked to ALS before, the authors note (Sasaki and Iwata, 1999; Mori et al., 2008; Sotelo-Silveira et al., 2009). They suggest that problems with TDP-43’s normal nuclear activity lead—indirectly, perhaps by altering gene expression—to disrupted mitochondrial trafficking or misregulated fission and fusion. This could then cause the mitochondrial aggregation.—Amber Dance.

Reference:
Xu YF, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, Rademakers R, Boylan K, Hutton M, McGowan E, Dickson DW, Lewis J, Petrucelli L. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010 Aug 11;30(32):15851-9. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad